Related Experiment Video
Updated: Apr 17, 2026
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
TM-1-1DP exerts protective effect against myocardial ischemia reperfusion injury via AKT-eNOS pathway
Hui-Chun Ku1, Shih-Yi Lee, Chi-Hsuan Chen
1Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Abstract:
Coronary heart disease remains a leading cause of death in the world. The demand on targeting therapy to reduce myocardial ischemia/reperfusion (I/R) injury is still urgent. The pathogenesis of I/R-induced myocardial injury is complicated. Reactive oxygen species (ROS) generation and inflammatory response activation participate in the development of I/R injury. Cell death occurs and finally leads to myocardial infarction. A newly phenolic aporphine alkaloid derivative, TM-1-1DP, was synthesized in our team. We aimed to investigate the effect of novel compound on myocardial I/R injury. Rats were subjected to 1-h coronary artery occlusion and followed by 2-h reperfusion. Adult rat cardimoycyte was isolated for the cell study, and H2O2 was added into culture medium to induce ROS stress. As compared to the sham group, TM-1-1DP-treated rats had better cardiac performance in association with less infarct size and cardiac injury markers after myocardial I/R. The protective effect is associated with the inhibition of inflammatory response, cell death-related pathway (caspase-3 and TNF-α), and the activation of AKT-eNOS pathway. The finding was further coincided with the cell study. TM-1-1DP treatment significantly alleviated ROS production and improved cell viability in cardiomyocyte after H2O2 exposure. The action of TM-1-1DP is via a nitric oxide (NO)-dependent manner, since NOS inhibitor, L-NAME, abolished the protective effect. We provide a new insight into this therapeutic potential for phenolic aporphine alkaloid in myocardial I/R.
Insights
A novel compound, TM-1-1DP, protects against heart damage from ischemia/reperfusion injury by reducing inflammation and cell death. This phenolic aporphine alkaloid shows therapeutic potential for myocardial infarction treatment.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Biochemistry
Background:
- Coronary heart disease is a major global health concern, necessitating urgent therapeutic strategies for myocardial ischemia/reperfusion (I/R) injury.
- The complex pathogenesis of I/R injury involves reactive oxygen species (ROS) generation and inflammatory responses, leading to cell death and myocardial infarction.
Purpose of the Study:
- To investigate the protective effects of a novel phenolic aporphine alkaloid derivative, TM-1-1DP, against myocardial I/R injury.
- To elucidate the underlying mechanisms of TM-1-1DP's action in both in vivo and in vitro models.
Main Methods:
- Rats underwent 1-hour coronary artery occlusion followed by 2-hour reperfusion to induce myocardial I/R injury.
- Adult rat cardiomyocytes were exposed to hydrogen peroxide (H2O2) to simulate oxidative stress.
- Cardiac performance, infarct size, cardiac injury markers, inflammatory cytokines (TNF-α), cell death pathways (caspase-3), ROS production, and cell viability were assessed.
- The role of nitric oxide (NO) was investigated using the NOS inhibitor L-NAME.
Main Results:
- TM-1-1DP treatment significantly improved cardiac performance, reduced infarct size, and decreased cardiac injury markers in I/R-injured rats.
- The compound inhibited inflammatory responses and cell death pathways, including caspase-3 and TNF-α.
- TM-1-1DP alleviated ROS production and enhanced cardiomyocyte viability under H2O2-induced oxidative stress.
- The protective effects were dependent on nitric oxide (NO) production, as L-NAME abolished the benefits.
Conclusions:
- TM-1-1DP demonstrates significant cardioprotective effects against myocardial I/R injury.
- Its mechanism involves the inhibition of inflammation and cell death, coupled with the activation of the AKT-eNOS pathway and NO-dependent processes.
- Phenolic aporphine alkaloid derivatives represent a promising therapeutic avenue for managing myocardial I/R injury.
